Compare Cardinal Health Inc (CAH) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs Procter & Gamble Co — how do they compare? Cardinal Health Inc trades at $240.6 (market cap $55.55B), while Procter & Gamble Co trades at $145.12 (market cap $340.39B). The key difference: Procter & Gamble Co is far larger — about 6.1× Cardinal Health Inc's market cap, and Procter & Gamble Co pays the higher dividend (2.97%). Which is the better fit depends on your goals.
| CAH | PG | |
|---|---|---|
Market Cap | $55.55B | $340.39B |
Sector | Health | Consumer Staples |
52-Week High | $239.71 | $167.18 |
52-Week Low | $146.04 | $138.10 |
Enterprise Value | $60.53B | $366.23B |
Dividend Yield | 0.86% | 2.97% |
Volume | — | 6,423,436 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $236.4, down 0.53% on the day, with a bullish technical outlook and strong earnings momentum after beating estimates for three consecutive quarters. The company reported $222.58B in revenue for 2025, with net income rising to $1.56B, and recently announced two home-care acquisitions to expand its at-Home Solutions segment. Analyst sentiment is positive, with a consensus price target of $262.80 and no sell ratings among 33 analysts.
The stock presents a favorable risk-reward profile with upside to the consensus target, supported by earnings beats and strategic growth initiatives. Key risks include high leverage with a debt-to-asset ratio of 16.09 in 2025 and thin net margins of 0.62%, which could pressure profitability if revenue growth slows or interest costs rise.
Procter & Gamble (PG) trades at $146.38, up 0.42% today, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.90. Revenue reached $84.28B in 2025, with a net income margin of 18.44% and robust cash flow from operations of $17.82B. Analyst consensus is bullish with a $161.20 price target, though valuation multiples like P/E of 22.12 and P/S of 4.08 are at premiums to peers.
The outlook for PG is positive due to steady earnings growth and dividend reliability, but risks include premium valuation concerns and soft demand headwinds. Investors may find opportunity in its defensive qualities amid market volatility, though near-term upside could be limited by technical resistance and modest revenue growth projections.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
